Experimental study of the possibility of reducing the cardiotoxic effects of “Mitomycin C” using an immobilized form of “Mitomycin C” and cytoprotector

The objective of this work was to investigate in experiments on laboratory rats the possibility of reducing the cardiotoxicity of the anticancer drug Mitomycin C by mixing it with Mesogel before injection and using Mexicor® as a cardioprotective agent. Materials and methods. To carry out the study, 70 male Wistar rats were used. The body weight of laboratory animals at the beginning of the experimental study ranged from 180 to 220 grams. Intraperitoneal administration of Mitomycin C at a dose of 4 mg/kg once at the start of the study was used. When Mitomycin C was administered together with Mesogel, the drugs were combined under aseptic conditions before intraperitoneal administration, and Mesogel was administered at a volume of 10.7 ml/kg. The drug Mexicor® was administered in the form of intramuscular injections at a dose of 60 mg/kg per day for 14 days. Results. After intraperitoneal injection of the drug "Mitomycin C" at a dose of 4 mg / kg, a noticeable decrease in the contractility of the rat myocardium during exercise tests was observed only on the 14th day. The use of "Mitomycin C" mixed with "Mesogel" during intraperitoneal administration had a positive effect, but did not completely exclude the manifestation of the cardiotoxic effects of "Mitomycin C". The greatest efficiency was demonstrated in groups of animals that received "Mitomycin C" in a mixture with "Mesogel" together with the cytoprotective drug "Mexicor®". Conclusion. The combination of "Mitomycin C" immobilisation in "Mesogel" together with the cytoprotective drug "Mexicor®" was found to eliminate the cardiotoxic effects of "Mitomycin C" to the greatest extent.

1. Gendlin G.E., Emelina E.I., Nikitin I.G., Vasyuk Yu.A. Modern view on cardiotoxicity of chemotherapeutics in oncology including anthracyclines.Russian Journal of Cardiology. 2017;(3):145-154. (in Russ.). DOI: 10.15829/1560-4071-2017-3-145-154

2. Alexandre J., Cautela J., Ederhy S., Damaj G.L., Salem J.E., Barlesi F., Farnault L., Charbonnier A. et al. Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio-Oncology Guidelines. J Am Heart Assoc. 2020;9(18):e018403. DOI: 10.1161/JAHA.120.018403

3. Armenian S.H., Armstrong G.T., Aune G., Chow E.J., Ehrhardt M.J., Ky B., Moslehi J, Mulrooney DA, Nathan PC, Ryan TD, van der Pal HJ, van Dalen EC, Kremer L.C.M. Cardiovascular Disease in Survivors of Childhood Cancer: Insights Into Epidemiology, Pathophysiology, and Prevention. J Clin Oncol. 2018;36(21):2135-2144. DOI: 10.1200/JCO.2017.76.3920

4. Schlitt A., Jordan K., Vordermark D., Schwamborn J., Langer T., Thomssen C. Cardiotoxicity and oncological treatments. Dtsch Arztebl Int. 2014;111(10): 161-168. DOI: 10.3238/arztebl.2014.0161

5. Bovelli D., Plataniotis G., Roila F., ESMO Guidelines Working Group. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Ann Oncol. 2010;21(Suppl 5):v277-282. DOI: 10.1093/annonc/mdq200

6. Brana I., Tabernero J. Cardiotoxicity. Ann Oncol. 2010;21(Suppl 7):vii173-179. DOI: 10.1093/annonc/mdq295

7. Kamphuis J.A.M., Linschoten M., Cramer M.J., Gort E.H., van Rhenen A., Asselbergs F.W., Doevendans P.A., Teske A.J. Cancer Therapy-Related Cardiac Dysfunction of Nonanthracycline Chemotherapeutics: What Is the Evidence? JACC CardioOncol. 2019;1(2):280-290. DOI: 10.1016/j.jaccao.2019.09.007

8. Oliveira G.H., Qattan M.Y., Al-Kindi S., Park S.J. Advanced heart failure therapies for patients with chemotherapy-induced cardiomyopathy. Circ Heart Fail. 2014;7(6):1050-1058. DOI: 10.1161/CIRCHEARTFAILURE.114.001292

9. Cautela J., Lalevée N., Ammar C., Ederhy S., Peyrol M., Debourdeau P., Serin D., Le Dolley Y. et al. Management and research in cancer treatment-related cardiovascular toxicity: Challenges and perspectives.Int J Cardiol. 2016;(224):366-375. DOI: 10.1016/j.ijcard.2016.09.046

10. Dorr R.T., Shipp N.G., Liddil J.D., Iyengar B.S., Kunz K.R., Remers W.A. Cardiotoxicity of mitomycin A, mitomycin C, and seven N7 analogs in vitro. Cancer Chemother Pharmacol. 1992;31(1):1-5. DOI: 10.1007/BF00695986

11. Lancellotti P., Suter T.M., López-Fernández T., Galderisi M., Lyon A.R., Van der Meer P., Cohen Solal A., Zamorano J.L. et al. Cardio-Oncology Services: rationale, organization, and implementation. Eur Heart J. 2019;40(22):1756-1763. DOI: 10.1093/eurheartj/ehy453

12. Zvyagin I.N., Frolova O.G., Lipatov V.A., Khvostovoy V.V., Inarkhov M.A. The influence of drugs deposited in the "Mesogel" agent on its anti-adhesion activity in the experiment. Sovremennyye problemy nauki i obrazovaniya. 2018;(6):89. (in Russ.)

13. Shekunova E.V., Kovaleva M.A., Makarova M.N., Makarov V.G. Dose selection in preclinical studies: cross-species dose conversion. The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2020;10(1):19-28. (in Russ.). DOI: 10.30895/1991-2919-2020-10-1-19-28

14. Gubanov K.K., Kovalev G.V., Paperna A.A.Comparative evaluation of the anti-ischemic action of verapamil in various models of myocardial ischemia. Farmakologiya i toksikologiya. 1991;54(4):21-23. (in Russ.)

15. Frolova O.G., Gladchenko M.P., Artyushkova E.B., Khvostovoy V.V., Kolesnikova A.M., Artyushkova E.V., Chernyatina M.A. The problem of cisplatin cardiotoxicity and the possibility of overcoming with the use of an immobilized form of cisplatin and a cytoprotector. Sovremennyye problemy nauki i obrazovaniya. 2016;(5):118. (in Russ.)

16. Dolci A., Dominici R., Cardinale D., Sandri M.T., Panteghini M. Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use. Am J Clin Pathol. 2008;130(5):688-695. DOI: 10.1309/AJCPB66LRIIVMQDR

17. Klebanov G.I., Lyubitskiy O.B., Vasil’yeva O.V., Klimov Yu.V., Penzulayeva O.B., Teplyashin A.S., Tolstykh M.P., Promorenko V.K. et al. Antioxidant properties of analogues of 3-oxypyridine: mexidol, emoxipin, proxipin. Voprosy meditsinskoy khimii. 2001;47(3):288-300 (in Russ.)